41 related articles for article (PubMed ID: 23328638)
1. Concordance of ATM (ataxia telangiectasia mutated) immunohistochemistry between biopsy or metastatic tumor samples and primary tumors in gastric cancer patients.
Kim HS; Kim MA; Hodgson D; Harbron C; Wellings R; O'Connor MJ; Womack C; Yin X; Bang YJ; Im SA; Lee BL; Kim WH
Pathobiology; 2013; 80(3):127-37. PubMed ID: 23328638
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Bang YJ; Im SA; Lee KW; Cho JY; Song EK; Lee KH; Kim YH; Park JO; Chun HG; Zang DY; Fielding A; Rowbottom J; Hodgson D; O'Connor MJ; Yin X; Kim WH
J Clin Oncol; 2015 Nov; 33(33):3858-65. PubMed ID: 26282658
[TBL] [Abstract][Full Text] [Related]
3. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
[TBL] [Abstract][Full Text] [Related]
4. Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker.
Kim JW; Im SA; Kim MA; Cho HJ; Lee DW; Lee KH; Kim TY; Han SW; Oh DY; Lee HJ; Kim TY; Yang HK; Kim WH; Bang YJ
Int J Cancer; 2014 Jan; 134(1):72-80. PubMed ID: 23649938
[TBL] [Abstract][Full Text] [Related]
5. Mutation at intronic repeats of the ataxia-telangiectasia mutated (ATM) gene and ATM protein loss in primary gastric cancer with microsatellite instability.
Kim HS; Choi SI; Min HL; Kim MA; Kim WH
PLoS One; 2013; 8(12):e82769. PubMed ID: 24324828
[TBL] [Abstract][Full Text] [Related]
6. NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M; Cleary JM; Shyr Y; Chao J; Uboha N; Cho M; Shields A; Pant S; Goff L; Spencer K; Kim E; Stein S; Kortmansky JS; Canosa S; Sklar J; Swisher EM; Radke M; Ivy P; Boerner S; Durecki DE; Hsu CY; LoRusso P; Lacy J
Br J Cancer; 2024 Feb; 130(3):476-482. PubMed ID: 38135713
[TBL] [Abstract][Full Text] [Related]
7. Histone and DNA Methylation as Epigenetic Regulators of DNA Damage Repair in Gastric Cancer and Emerging Therapeutic Opportunities.
De Marco K; Sanese P; Simone C; Grossi V
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894343
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapies and Developing Precision Medicine in Gastric Cancer.
Pihlak R; Fong C; Starling N
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370858
[TBL] [Abstract][Full Text] [Related]
9. Detection of a Novel
Ferrari A; Fiocca R; Bonora E; Domizio C; Fonzi E; Angeli D; Domenico Raulli G; Mattioli S; Martinelli G; Molinari C
Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107676
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy and olaparib in combination for carcinoma of the oesophagus: A phase I study.
Sheikh H; Ryder D; Bateman A; Chalmers A; Jackson A
Clin Transl Radiat Oncol; 2023 May; 40():100614. PubMed ID: 36949958
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
Kwon M; Kim G; Kim R; Kim KT; Kim ST; Smith S; Mortimer PGS; Hong JY; Loembé AB; Irurzun-Arana I; Koulai L; Kim KM; Kang WK; Dean E; Park WY; Lee J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35790315
[TBL] [Abstract][Full Text] [Related]
12. Early
Sahgal P; Huffman BM; Patil DT; Chatila WK; Yaeger R; Cleary JM; Sethi NS
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885025
[TBL] [Abstract][Full Text] [Related]
13. State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer.
Basile D; Simionato F; Cappetta A; Garattini SK; Roviello G; Aprile G
Biologics; 2021; 15():451-462. PubMed ID: 34764633
[TBL] [Abstract][Full Text] [Related]
14. Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.
Fong CY; Chau I
Pharmacogenomics; 2021 Jul; 22(11):703-726. PubMed ID: 34120461
[TBL] [Abstract][Full Text] [Related]
15. Development of an Immunohistochemical Assay to Detect the Ataxia-Telangiectasia Mutated (ATM) Protein in Gastric Carcinoma.
Miller RM; Nworu C; McKee L; Balcerzak D; Pham L; Pugh J; Liu YZ; Gustafson H; Marwah E; Lamb T; Clements J
Appl Immunohistochem Mol Morphol; 2020 Apr; 28(4):303-310. PubMed ID: 31206368
[TBL] [Abstract][Full Text] [Related]
16. Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.
Klempner SJ; Bhangoo MS; Luu HY; Kim ST; Chao J; Kim KM; Lee J
J Gastrointest Oncol; 2018 Dec; 9(6):1198-1206. PubMed ID: 30603142
[TBL] [Abstract][Full Text] [Related]
17. State-of-the-art strategies for targeting the DNA damage response in cancer.
Pilié PG; Tang C; Mills GB; Yap TA
Nat Rev Clin Oncol; 2019 Feb; 16(2):81-104. PubMed ID: 30356138
[TBL] [Abstract][Full Text] [Related]
18. The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Flynn M; Young K; Cunningham D; Starling N
Ther Adv Med Oncol; 2018; 10():1758835918786228. PubMed ID: 30034550
[TBL] [Abstract][Full Text] [Related]
19. WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation.
Kim JJ; Lee SB; Yi SY; Han SA; Kim SH; Lee JM; Tong SY; Yin P; Gao B; Zhang J; Lou Z
Cell Res; 2017 Feb; 27(2):274-293. PubMed ID: 27958289
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
